Ascendis Pharma A/SASNDNASDAQ
Loading
Gross Profit Growth Under PressureDecelerating
Percentile Rank54
3Y CAGR-23.2%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
-23.2%/yr
vs -31.5%/yr prior
Acceleration
+8.4pp
Accelerating
Percentile
P54
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.96% |
| Q3 2025 | 51.09% |
| Q2 2025 | 51.73% |
| Q1 2025 | -47.82% |
| Q4 2024 | 242.88% |
| Q3 2024 | 90.08% |
| Q2 2024 | -72.22% |
| Q1 2024 | -25.30% |
| Q4 2023 | 190.91% |
| Q3 2023 | 17.94% |
| Q2 2023 | 18.97% |
| Q1 2023 | 62.89% |
| Q4 2022 | 30.79% |
| Q3 2022 | 167.97% |
| Q2 2022 | 96.51% |
| Q1 2022 | 87.92% |
| Q4 2021 | 23.45% |
| Q3 2021 | 8.90% |
| Q2 2021 | 37.00% |
| Q1 2021 | 100.40% |
| Q4 2020 | -201.16% |
| Q3 2020 | 1.35% |
| Q2 2020 | -12.39% |
| Q1 2020 | -2305.42% |
| Q4 2019 | 11.77% |
| Q3 2019 | 105.52% |
| Q2 2019 | -850.18% |
| Q1 2019 | -48.51% |
| Q4 2018 | 52475.00% |
| Q3 2018 | 11.11% |
| Q2 2018 | -35.71% |
| Q1 2018 | -90.00% |
| Q4 2017 | -35.48% |
| Q3 2017 | -2.25% |
| Q2 2017 | 19.35% |
| Q1 2017 | -64.33% |
| Q4 2016 | -10.78% |
| Q3 2016 | 2.90% |
| Q2 2016 | -9.70% |
| Q1 2016 | -36.37% |